We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

14 hedge funds and large institutions have $2.27M invested in NeuBase Therapeutics, Inc. Common Stock in 2013 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

150% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 2

27% more funds holding

Funds holding: 11 → 14 (+3)

27% more capital invested

Capital invested by funds: $1.79M → $2.27M (+$483K)

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

Holders
14
Holders Change
+3
Holders Change %
+27.27%
% of All Funds
0.41%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
3
Reduced
3
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$426K
2
PPCM
Pillar Pacific Capital Management
California
+$139K
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$86.3K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$64.8K
5
Morgan Stanley
Morgan Stanley
New York
+$21.6K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$95.6K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$87K
3
FNBT
FineMark National Bank & Trust
Florida
-$46.3K
4
First Manhattan
First Manhattan
New York
-$13K
5
Deutsche Bank
Deutsche Bank
Germany
-$12.3K
Name Holding Trade Value Shares
Change 		Change in
Stake
Goldman Sachs
1
Goldman Sachs
New York
$1.07M -$95.6K -31 -8%
Vanguard Group
2
Vanguard Group
Pennsylvania
$529K +$426K +138 +460%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$214K +$64.8K +21 +45%
PPCM
4
Pillar Pacific Capital Management
California
$140K +$139K +45 New
State Street
5
State Street
Massachusetts
$89K – – –
T. Rowe Price Associates
6
T. Rowe Price Associates
Maryland
$88K +$86.3K +28 New
FNBT
7
FineMark National Bank & Trust
Florida
$47K -$46.3K -15 -50%
TRCT
8
Tower Research Capital (TRC)
New York
$24K +$18.5K +6 +300%
Morgan Stanley
9
Morgan Stanley
New York
$21K +$21.6K +7 New
U
10
UBS
Switzerland
$15K – – –
Deutsche Bank
11
Deutsche Bank
Germany
$11K -$12.3K -4 -50%
BIT
12
BlackRock Institutional Trust
California
$11K +$9.25K +3 New
ACM
13
Aviance Capital Management
Florida
$9K +$9.25K +3 New
Wells Fargo
14
Wells Fargo
California
$3K – – –
Susquehanna International Group
15
Susquehanna International Group
Pennsylvania
– -$87K -27 Closed
First Manhattan
16
First Manhattan
New York
– -$13K -4 Closed

NBSE Hedge Fund Activity: Q4 2013 in Review

14 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q4 2013, worth a combined $2.27M — up 27% from $1.79M a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new NBSE positions and 2 closed out — a net gain of 3 holders — while 3 added to existing stakes and 3 trimmed.

The largest buyer was Vanguard Group, adding an estimated $426K. The largest seller was Goldman Sachs, cutting an estimated $95.6K.

  • 14 institutional investors held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q4 2013, up from 11 in Q3 2013.
  • Funds reported $2.27M of NeuBase Therapeutics, Inc. Common Stock stock for Q4 2013, up 27% quarter-over-quarter.
  • 5 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q4 2013 and 2 closed out, a net change of +3 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock buyer in Q4 2013 was Vanguard Group, an estimated $426K added.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q4 2013 was Goldman Sachs, an estimated $95.6K sold.

Based on aggregated 13F filings for Q4 2013.